Sanuwave Health Reports Record Q3 Performance
In a significant milestone, Sanuwave Health, Inc. (NASDAQ: SNWV), a pioneer in innovative FDA-approved wound care products, has reported its financial outcomes for the third quarter of fiscal year 2025. The company achieved an impressive revenue of $11.5 million, showing a remarkable 22% increase from $9.4 million in the same quarter of the previous year. This achievement marks the highest quarterly revenue ever recorded in the company's history.
Profitability and Sales Growth
The gross margin for Q3 2025 reached 77.9%, compared to 75.5% in Q3 2024, indicating a healthy expansion in profitability. However, the GAAP operating income for this quarter was $1.5 million, slightly lower than the $2.0 million recorded in Q3 2024. This decline was attributed to stock-based compensation costs amounting to $1.4 million in Q3 2025, highlighting a change in operational expenditures.
Record System Sales
The sales of UltraMist® systems also set a company record, with 155 units sold in Q3 2025, surpassing the previous record of 124 units sold in Q3 2024. Additionally, UltraMist® consumables revenue surged by 26%, totaling $6.8 million as compared to $5.4 million during the preceding quarter.
Favorable Outlook and Market Adaptation
Sanuwave's management is optimistic about maintaining revenue growth momentum. The company has provided guidance projecting fourth-quarter revenues between $13 million and $14 million, taking into account the expected effects of proposed reimbursement changes within the advanced wound care sector. CEO Morgan Frank emphasized that while the industry faced uncertainties, the positive feedback and robust sales pipeline indicate a strong interest from customers and distribution partners.
Response to Reimbursement Changes
Despite facing challenges related to reimbursement policy shifts, particularly concerning skin substitutes, Sanuwave's sales growth remains commendable. The recent final rule published by CMS on Medicare physician fees for 2026 aligns with the company’s projections and is expected to facilitate a smoother market transition, allowing for adjustments in advanced wound care practices.
Financial Highlights
In addition to record revenues, the company noted a net income of $10.3 million for Q3, a significant rebound from the net loss of $20.7 million reported in the third quarter of 2024. This impressive turnaround is attributed to improvements in the fair value of derivative liabilities and a successful sale of specific shockwave patents that generated $5 million.
Moreover, Sanuwave's Adjusted EBITDA came in at $3.5 million for Q3, compared to $2.1 million in the previous year. These financial challenges highlight the company's resilience and commitment to restoring profitability.
About Sanuwave
Sanuwave Health is dedicated to the research, development, and commercialization of groundbreaking medical systems designed for skin repair, regeneration, and wound healing. Their innovative approach utilizes patented energy transfer technologies across a spectrum of medical applications, including wound care, orthopedic treatments, and cosmetic procedures.
Frequently Asked Questions
What were Sanuwave's total revenues for Q3 2025?
Sanuwave reported total revenues of $11.5 million, a 22% increase from $9.4 million in Q3 2024.
How many UltraMist® systems were sold in Q3 2025?
155 UltraMist® systems were sold in Q3 2025, setting an all-time quarterly record for the company.
What is Sanuwave's revenue outlook for Q4 2025?
The company provides a revenue guidance of $13-$14 million for Q4 2025.
What is Sanuwave focused on developing?
Sanuwave focuses on non-invasive medical systems for wound healing, musculoskeletal tissue repair, and vascular structure regeneration.
How did Sanuwave's operating income for Q3 2025 compare to last year?
The GAAP operating income in Q3 2025 was $1.5 million, compared to $2.0 million in Q3 2024.
